Nucleotide analogs as novel anti-hepatitis B virus agents

被引：16

作者：

Iyer, RP

Padmanabhan, S

Zhang, GR

Morrey, JD

Korba, BE

机构：

[1] Spring Bank Technol Inc, Milford, MA 01757 USA

[2] Utah State Univ, Inst Antiviral Res, Dept Anim Dairy & Vet Sci, Logan, UT 84322 USA

[3] Georgetown Univ, Div Mol Virol & Immunol, Rockville, MD USA

来源：

CURRENT OPINION IN PHARMACOLOGY | 2005年 / 5卷 / 05期

关键词：

D O I：

10.1016/j.coph.2005.04.019

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

During the past decade, nucleotide analogs have emerged as novel antiviral agents against hepatitis B virus. Adefovir dipivoxil, a prototype phosphonate analog, has been approved for chronic hepatitis B virus therapy, and additional phosphonate analogs and di- and tri-nucleotides are under development. Several innovative prodrug derivatizations have also been reported to improve the oral bioavailability of nucleotide analogs, which usually carry a negative charge.

引用

收藏

页码：520 / 528

页数：9

相关论文

共 48 条

[1] Rebound of hepatitis B virus replication in HepG2 cells after cessation of antiviral treatment [J].

Abdelhamed, AM ;

Kelley, CM ;

Miller, TG ;

Furman, PA ;

Isom, HC .

JOURNAL OF VIROLOGY, 2002, 76 (16) :8148-8160

[2] Identification and characterization of mutations in hepatitis B virus resistant to lamivudine [J].

Allen, MI ;

Deslauriers, M ;

Andrews, CW ;

Tipples, GA ;

Walters, KA ;

Tyrrell, DLJ ;

Brown, N ;

Condreay, LD .

HEPATOLOGY, 1998, 27 (06) :1670-1677

[3] Are 5′-O-Carbamate-2′,3′-dideoxythiacytidine new anti-HIV and anti-HBV nucleoside drugs or prodrugs? [J].

Anastasi, C ;

Vlieghe, P ;

Hantz, O ;

Schorr, O ;

Pannecouque, C ;

Witvrouw, M ;

De Clercq, E ;

Clayette, P ;

Dereuddre-Bosquete, N ;

Dormont, D ;

Gondois-Rey, F ;

Hirsch, I ;

Kraus, JL .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (15) :2459-2463

[4]

Cahard D, 2004, MINI-REV MED CHEM, V4, P371

[5] A novel class of phosphonate nucleosides. 9-[(1-phosphonomethoxycyclopropyl)methyl]guanine as a potent and selective anti-HBV agent [J].

Choi, JR ;

Cho, DG ;

Roh, KY ;

Hwang, JT ;

Ahn, S ;

Jang, HS ;

Cho, WY ;

Kim, KW ;

Cho, YG ;

Kim, J ;

Kim, YZ .

JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (11) :2864-2869

[6] Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus [J].

Dore, GJ ;

Cooper, DA ;

Pozniak, AL ;

DeJesus, E ;

Zhong, LJ ;

Miller, MD ;

Lu, B ;

Cheng, AK .

JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (07) :1185-1192

[7]

Drontle DP, 2004, MINI-REV MED CHEM, V4, P409

[8] Design, synthesis, and characterization of a series of cytochrome P450 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver [J].

Erion, MD ;

Reddy, KR ;

Boyer, SH ;

Matelich, MC ;

Gornez-Galeno, J ;

Lemus, RH ;

Ugarkar, BG ;

Colby, TJ ;

Schanzer, J ;

van Poelje, PD .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2004, 126 (16) :5154-5163

[9]

FLEISCHER R, 2003, CLIN INFECT DIS, V2, P227

[10] Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: Implications for vaccination programs [J].

Goldstein, ST ;

Alter, MJ ;

Williams, IT ;

Moyer, LA ;

Judson, FN ;

Mottram, K ;

Fleenor, M ;

Ryder, PL ;

Margolis, HS .

JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (06) :713-719

← 1 2 3 4 5 →